|
WO2007042035A2
|
|
Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
|
|
CN101304732A
|
|
Controlled release pharmaceutical compositions comprising a fumaric acid ester
|
|
US2008299196A1
|
|
Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
|
|
WO2007006308A1
|
|
Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
|
|
EP1915334A2
|
|
Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
|
|
WO2006063596A2
|
|
A composition comprising pp for the treatment of gastrointestinal disorders
|
|
WO2006050730A1
|
|
Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
|
|
US2008004344A1
|
|
Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
|
|
CN101056624A
|
|
Controlled release pharmaceutical compositions comprising a fumaric acid ester
|
|
WO2005110457A2
|
|
Treatment of eating disorders and induction of lipolysis
|
|
AU2005244475A1
|
|
A composition comprising pyy for the treatment of gastrointestinal disorders
|
|
WO2005110454A2
|
|
Protective binding members of pyy for the treatment of metabolic disorders
|
|
WO2005097830A2
|
|
Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
|
|
WO2005079888A2
|
|
Delivery device for delivering pyy
|
